Circumvention of immunity to the adenovirus major coat protein hexon

Journal of Virology

Volumn 72, Issue 8, 1998, Pages 6875-6879

  Roy, Soumitra ^a   Shirley, Pamela S ^a   McClelland, Alan ^a   Kaleko, Michael ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CAPSID PROTEIN; COAT PROTEIN; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; GENE THERAPY; IMMUNITY; IMMUNOBLOTTING; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROTYPE;

EID: 0031903186     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.8.6875-6879.1998     Document Type: Article

References (27)

1. Athappilly, F. K., R. Murali, J. J. Rux, Z. Cai, and R. M. Burnett. 1994. The refined crystal structure of hexon, the major coat protein of adenovirus type 2, at 2.9 Å resolution. J. Mol. Biol. 242:430-455.
2. Bailey, A., and V. Mautner. 1994. Phylogenetic relationships among adenovirus serotypes. Virology 205:438-452.
3. Connelly, S., J. M. Gardner, R. M. Lyons, A. McClelland, and M. Kaleko. 1996. Sustained expression of therapeutic levels of human factor VIII in mice. Blood 87:4671-4677.
4. Crawford-Miksza, L., and D. P. Schnurr. 1996. Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. J. Virol. 70:1836-1844.
5. Crawford-Miksza, L. K., and D. P. Schnurr. 1996. Adenovirus serotype evolution is driven by illegitimate recombination in the hypervariable regions of the hexon protein. Virology 224:357-367.
6. Dai, Y., E. M. Schwarz, D. Gu, W. Zhang, N. Sarvetnick, and I. M. Verma. 1995. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc. Natl. Acad. Sci. USA 92:1401-1405.
7. Gall, J., A. Kass-Eisler, L. Leinwand, and E. Falck-Pedersen. 1996. Adeno-virus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J. Virol. 70:2116-2123.
8. Gorziglia, M. I., M. J. Kadan, S. Yei, J. Lim, G. M. Lee, R. Luthra, and B. C. Trapnell. 1996. Elimination of both E1 and E2a from adenovirus vectors further improves prospects for in vivo human gene therapy. J. Virol. 70:4173-4178.
9. Hierholzer, J. C., Y. O. Stone, and J. R. Broderson. 1991. Antigenic relationships among the 47 human adenoviruses determined in reference horse antisera. Arch. Virol. 121:179-197.
10. Horwitz, M. S. 1990. Adenoviridae and their replication, p. 1679-1721. In B. N. Fields and D. M. Knipe (ed.), Virology. Raven Press, New York, N.Y.
11. Kass-Eisler, A., E. Falck-Pedersen, D. H. Elfenbein, M. Alvira, P. M. Buttrick, and L. A. Leinwald. 1994. The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. Gene Ther. 1:395-402.
12. Kass-Eisler, A., L. Leinwand, J. Gall, B. Bloom, and E. Falck-Pedersen. 1996. Circumventing the immune response to adenovirus-mediated gene therapy. Gene Ther. 3:154-162.
13. Kozarsky, K. F., D. R. McKinley, L. L. Austin, S. E. Raper, L. D. Stratford-Perricaudet, and J. M. Wilson. 1994. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J. Biol. Chem. 269:13695-13702.
14. Mastrangeli, A., B. Harvey, J. Yao, G. Wolff, I. Kovesdi, R. G. Crystal, and E. Falck-Pedersen. 1996. "Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum. Gene Ther. 7:79-87.
15. Norby, E. 1969. The structural and functional diversity of adenovirus capsid components. J. Gen. Virol. 5:221-236.
16. Roberts, M. M., J. L. White, M. G. Grütter, and R. M. Burnett. 1986. Three-dimensional structure of the adenovirus major coat protein hexon. Science 232:1148-1151.
17. Schmitz, H., R. Wigand, and W. Heinrich. 1983. Worldwide epidemiology of human adenovirus infections. Am. J. Epidemiol. 117:455-466.
18. Smith, T. A. G., M. G. Mehaffey, D. B. Kayda, J. M. Saunders, S. Yei, B. C. Trapnell, A. McClelland, and M. Kaleko. 1993. Adenovirus mediated expression of therapeutic plasma levels of human factor IX. Nat. Genet. 5:397-402.
19. Smith, T. A. G., B. D. White, J. M. Gardner, M. Kaleko, and A. McClelland. 1996. Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Ther. 3:496-502.
20. Wohlfart, C. 1988. Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms. J. Virol. 62:2321-2328.
21. Yang, Y., K. Greenough, and J. M. Wilson. 1996. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther. 3:412-420.
22. Yang, Y., S. E. Haecker, Q. Su, and J. M. Wilson. 1996. Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. Hum. Mol. Genet. 5:1703-1712.
23. Yang, Y., Q. Li, H. C. J. Ertl, and J. M. Wilson. 1995. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69:2004-2015.
24. Yang, Y., Q. Su, I. S. Grewal, R. Schilz, R. A. Flavell, and J. M. Wilson. 1996. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J. Virol. 70:6370-6377.
25. Yang, Y., G. Trinchieri, and J. M. Wilson. 1995. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat. Med. 1:890-893.
26. Yang, Y., and J. M. Wilson. 1996. CD40 ligand-dependent T cell activation: requirement of B7-CD28 signalling through CD40. Science 273:1862-1864.
27. Yei, S., N. Mittereder, K. Tang, C. O'Sullivan, and B. C. Trapnell. 1994. Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. Gene Ther. 1:192-200.